Am. Simpson et al., GENE-THERAPY OF DIABETES - GLUCOSE-STIMULATED INSULIN-SECRETION IN A HUMAN HEPATOMA-CELL LINE (HEP G2INSLG), Gene therapy, 4(11), 1997, pp. 1202-1215
In order to design a feasible somatic cell gene delivery system for th
e treatment of type I diabetes, a suitable cell type needs to be deter
mined. We have previously shown that the stable transfection of the fu
ll-length insulin cDNA into the human liver cell line, (HEP G2ins) res
ulted in synthesis, storage and acute regulated release of insulin to
analogues of cAMP, but not to the physiological stimulus glucose. In a
ttempting to explain the lack of glucose responsiveness of the HEP G2i
ns cells we have stably transfected these cells with the human islet g
lucose transporter GLUT 2 (HEP G2inslg cells). The HEP G2inslg cell cl
ones exhibit glucose-stimulated insulin secretion and glucose potentia
tion of the secretory response to nonglucose secretagogues. While gluc
ose responsiveness commenced at a lower concentration than normal isle
ts, a secretion curve approaching normal physiological conditions was
generated. Immunoelectron microscopy revealed the presence of insulin-
containing granules, similar in size and appearance to those of the no
rmal beta cell. These results demonstrate that while it is most likely
that the HEP G2inslg cell line predominately secretes insulin via the
constitutive pathway, significant acute regulated release was seen in
response to glucose, and thus represents significant progress in the
creation of a genetically-engineered 'artificial beta cell' from a hum
an hepatocyte cell line.